Literature DB >> 1735815

Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis.

R Schneider1, B A Lang, B J Reilly, R M Laxer, E D Silverman, D Ibanez, C Bombardier, C M Roifman.   

Abstract

We retrospectively reviewed the charts and radiographs of 38 patients with systemic-onset juvenile rheumatoid arthritis, attempting to identify early in the disease course the clinical and laboratory observations most predictive of the later development of destructive arthritis. In 12 of the patients, destructive arthritis developed within 2 years of disease onset. When first examined, these patients could not readily be differentiated from those in whom joint destruction did not develop, but they more commonly had hepatosplenomegaly (p less than 0.04), serositis (p less than 0.01), and a lower mean serum albumin concentration (26.7 vs 31.3 gm/L; p less than 0.02). However, by 6 months after onset, patients with destructive arthritis more frequently had persistent systemic symptoms (92% vs 12%; p less than 0.0001), polyarthritis (67% vs 19%; p less than 0.0005), a lower mean hemoglobin level (95 vs 114 gm/L; p less than 0.001), a higher mean leukocyte count (21.2 vs 10 x 10(9)/L; p less than 0.0003), a higher mean platelet count (794 vs 400 x 10(9)/L; p less than 0.0001), and a higher mean erythrocyte sedimentation rate (43 vs 24 mm/hr; p less than 0.05). Multivariate analysis of the results at 6 months revealed that persistent systemic symptoms and a platelet count greater than or equal to 600 x 10(9)/L were the variables most highly predictive of the later development of joint destruction. We conclude that patients at high risk for the development of destructive arthritis may be identified within 6 months of disease onset, thereby indicating the need for more aggressive early therapy.

Entities:  

Mesh:

Year:  1992        PMID: 1735815     DOI: 10.1016/s0022-3476(05)80427-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Methotrexate therapy in systemic-onset juvenile rheumatoid arthritis in Saudi Arabia: a retrospective analysis.

Authors:  W al-Sewairy; A al-Mazyed; S al-Balaa; S Bahabri
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 2.  [Still's disease in children and adults].

Authors:  C M Hedrich; C Günther; M Aringer
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

3.  Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.

Authors:  Esi Morgan DeWitt; Yukiko Kimura; Timothy Beukelman; Peter A Nigrovic; Karen Onel; Sampath Prahalad; Rayfel Schneider; Matthew L Stoll; Sheila Angeles-Han; Diana Milojevic; Kenneth N Schikler; Richard K Vehe; Jennifer E Weiss; Pamela Weiss; Norman T Ilowite; Carol A Wallace
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-07       Impact factor: 4.794

Review 4.  2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.

Authors:  Timothy Beukelman; Nivedita M Patkar; Kenneth G Saag; Sue Tolleson-Rinehart; Randy Q Cron; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Alberto Martini; C Egla Rabinovich; Nicolino Ruperto
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

Review 5.  [Still's disease in children and adults].

Authors:  C M Hedrich; C Günther; M Aringer
Journal:  Hautarzt       Date:  2017-06       Impact factor: 0.751

Review 6.  Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis.

Authors:  Laura Marinela Ailioaie; Constantin Ailioaie; Gerhard Litscher
Journal:  Int J Mol Sci       Date:  2022-04-12       Impact factor: 6.208

7.  Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).

Authors:  Peter A Nigrovic; Timothy Beukelman; George Tomlinson; Brian M Feldman; Laura E Schanberg; Yukiko Kimura
Journal:  Clin Trials       Date:  2018-03-15       Impact factor: 2.486

8.  Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.

Authors:  Xuefeng B Ling; Kenneth Lau; Chetan Deshpande; Jane L Park; Diana Milojevic; Claudia Macaubas; Chris Xiao; Viorica Lopez-Avila; John Kanegaye; Jane C Burns; Harvey Cohen; James Schilling; Elizabeth D Mellins
Journal:  Clin Proteomics       Date:  2010-09-30       Impact factor: 3.988

9.  Systemic arthritis in children: a review of clinical presentation and treatment.

Authors:  R Gurion; T J A Lehman; L N Moorthy
Journal:  Int J Inflam       Date:  2011-12-25

Review 10.  Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition.

Authors:  Sriharsha Grevich; Susan Shenoi
Journal:  Adolesc Health Med Ther       Date:  2017-11-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.